Biotechnology: will it break the health care bank?
Pharmaceuticals traditionally have been viewed as a cost-effective component in medicine's technological armamentarium. The use of pharmaceuticals has been estimated to account for 6-8 percent of the nation's total expenditures on health care. The first wave of pharmaceuticals/biologicals that has been produced by the biotechnology industry has offered therapies that can provide much benefit to patients, but it has also raised concern about the cost of these new recombinant drugs. In addition to pricing, methods of promotion and modifications in the FDA approval process have raised concerns.
McGivney
W T
WT
Aetna Health Plans, Hartford, CT.
D001709:Biotechnology / Q000191:economics* / Q000592:standards; D003362:Cost-Benefit Analysis; D017277:Drug Approval; D016527:Drug Costs / Q000639:trends*; D006801:Humans; D011994:Recombinant Proteins / Q000191:economics; D014481:United States; D014486:United States Food and Drug Administration